Recently Authorized Therapeutics for COVID-19

Oral Medications:

**Paxlovid and Molnupiravir Distribution and Use**

DSHS has been allocated limited quantities of both of these oral medications for treatment of high-risk patients with mild/moderate COVID-19 infection. Both medications must be prescribed only within the criteria set by the FDA under the Emergency Use Authorization (EUA). Due to the limited quantity of medication available across the country, the National Institutes of Health (NIH) have created guidelines for *Patient Prioritization for Outpatient Anti-SARS CoV-2 Therapies or Preventive Strategies When There Are Logistical or Supply Constraints*. Health Care Providers can refer to the maps created by DSHS to determine the pharmacies that will have supply of these medications on hand for distribution to patients (see [DSHS Therapeutics](#)).

**Paxlovid Clinical Details**

Paxlovid is an oral medication used for treatment of people with mild/moderate COVID-19 infection and high risk of progression to severe COVID-19 (including hospitalization and death). Treatment consists of 3 pills taken twice daily for 5 days. Treatment must start within 5 days of symptom onset. It is authorized for children age 12 and older (weighing at least 40 kg) and adults. Special precautions should be taken for certain health conditions and for people taking certain medications. Details of prescribing indications, contraindications and warnings/precautions for prescribing can be found in the [Health Care Provider Fact Sheet](#) and the FDA has also created a [FAQ document](#) for reference.

**Molnupiravir Clinical Details**

Molnupiravir is an oral medication used for treatment of people with mild/moderate COVID-19 infection and high risk of progression to severe COVID-19 (including hospitalization and death). Treatment consists of 4 pills taken twice daily for 5 days. Treatment must start within 5 days of symptom onset. Molnupiravir is authorized for use in adults 18 and older. Special precautions should be taken in prescribing to women and men of child-bearing age as this medication was found in animal studies to cause...
fetal harm. Details of prescribing indications, contraindications and warnings/precautions for prescribing can be found in the Health Care Provider Fact Sheet and the FDA has also created a FAQ document for reference.

Pre-Exposure Prophylaxis Monoclonal Antibody for Immunocompromised People:

Evusheld Distribution and Use

DSHS has been allocated limited quantities of this monoclonal antibody for pre-exposure prophylaxis for COVID-19 in people who are immunocompromised and are not expected to mount an adequate immune response to the COVID-19 vaccine. Evusheld is not a substitute for vaccination in individuals who have been recommended to be vaccinated, but can be used in an individual with a history of a severe allergic reaction to a COVID-19 vaccine and who cannot complete the vaccination series. DSHS has distributed this monoclonal antibody to sites across the state who care for this population of patients. This monoclonal antibody must be given only within the criteria set by the FDA under the Emergency Use Authorization (EUA). Due to the limited quantity of this medication available across the country, the National Institutes of Health (NIH) have created guidelines for Patient Prioritization for Outpatient Anti-SARS CoV-2 Therapies or Preventive Strategies When There Are Logistical or Supply Constraints. Health Care Providers can refer to the maps created by DSHS to determine facilities who have been allocated this monoclonal antibody (see DSHS Therapeutics).

Evusheld Clinical Details

Evusheld is monoclonal antibody used for pre-exposure prophylaxis in people children 12 years of age and older (weighing at least 40 kg) and adults who are immunocompromised and are not expected to mount an adequate immune response to the COVID-19 vaccines available. Evusheld is not a substitute for vaccination in individuals who have been recommended to be vaccinated but can be used in an individual with a history of severe allergic reaction to a COVID-19 vaccine and who cannot complete the vaccination series. It is given as 2 intramuscular injections dosed every 6 months. Details of prescribing indications, contraindications and warnings/precautions for prescribing can be found in the Health Care Provider Fact Sheet and the FDA has also created a FAQ document for reference.